FDA Warning Letter Cites Alcon’s Ciprodex Promotion For Unfounded Superiority Claims
This article was originally published in The Pink Sheet Daily
Agency also notes omission of risk information for the otitis media treatment.
You may also be interested in...
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.
FDA extends the combination vaccine’s action date for the second time, this time requesting lab validation information relating to the pertussis component, but not directly related to Pentacel.